Endava has extended its partnership with SOPHiA GENETICS to enhance the SOPHiA DDM™ platform, advancing precision medicine through improved genomic data analytics and AI-driven automation. The collaboration supports personalised cancer care and multimodal data integration, expanding global access to next-generation healthcare solutions.
Endava, a technology services company known for its AI-native solutions, has deepened its strategic partnership with SOPHiA GENETICS, a cloud-native healthcare technology firm specialising in data-driven medicine. This extended collaboration focuses on advancing genomic analytics and expanding the reach of precision medicine worldwide.
Since 2022, Endava has supported SOPHiA GENETICS in enhancing the SOPHiA DDM™ platform, improving its speed, accuracy, and scalability for data analysis. The partnership has also fostered the integration of diverse data types—including genomic, clinical, biological, and radiomic—enabling healthcare institutions to generate comprehensive insights from complex datasets. Enhanced visualisation tools within the platform now assist healthcare professionals in making more precise clinical decisions, which contributes to better patient outcomes.
The collaboration has broadened access to these advanced data analytics, allowing a growing number of hospitals, laboratories, and biopharmaceutical organisations to benefit from next-generation healthcare solutions.
Focus on personalised cancer care and AI innovations
With the partnership entering its fourth year and a new two-year engagement signed in 2025, the two companies continue to innovate. Endava aids SOPHiA GENETICS in developing personalised cancer care by aligning treatments with patient-specific genomic profiles. Further platform advancements include enabling multimodal data visualisation to improve clinical decision-making accuracy.
In addition, the collaboration leverages cutting-edge AI to enhance automation, optimise internal support processes, and improve test case generation. The integration of offshore capabilities supports scalability and flexibility, meeting the global demand for healthcare data solutions.
Commitment to advancing healthcare access and outcomes
Isabela Buhai, Client Director for Healthcare and Life Sciences at Endava, states, “We’re proud to continue partnering with SOPHiA GENETICS to support their vision for precision medicine. This collaboration reflects our shared commitment to improving access, insight and impact in healthcare.”
SOPHiA GENETICS’ Chief Technology Officer, Abhimanyu Verma, adds, “The partnership with Endava has supported our mission to enable data-driven medicine at scale. The team’s deep expertise in cloud computing, AI-driven automation and advanced analytics has helped us strengthen the SOPHiA DDM™ platform for the healthcare community on a global scale.”
As healthcare systems increasingly rely on complex data integration, this partnership remains focused on delivering accessible, scalable, and secure technology solutions. These efforts aim to enhance clinical decision-making and improve patient outcomes worldwide.
About Endava
Endava is a global technology services company headquartered in London, United Kingdom. Founded in 2000, it has grown to become a leading provider of next-generation IT services, specialising in digital transformation, agile software development, and automation solutions. The company operates delivery centres across Eastern Europe, Latin America, and Asia Pacific, while maintaining close-to-client offices in North America and Western Europe .
As of June 30, 2024, Endava employed 12,085 professionals, reflecting a modest year-over-year increase. The company serves a diverse range of industries, including finance, healthcare, media, telecommunications, and retail. Endava’s multidisciplinary teams combine world-class engineering with deep industry expertise to deliver tailored solutions that drive innovation and transformation for its clients.
About SOPHiA GENETICS
SOPHiA GENETICS is a Swiss-founded, cloud-native healthcare technology company headquartered in Rolle, Switzerland, with additional offices in Boston, Massachusetts, and Bidart, France. Established in 2011 by biologists Dr. Jurgi Camblong, Prof. Lars Steinmetz, and Dr. Pierre Hutter, the company is dedicated to transforming patient care through data-driven medicine. Its flagship product, the SOPHiA DDM™ (Data-Driven Medicine) Platform, leverages artificial intelligence to analyse complex genomic and multimodal data, providing real-time, actionable insights to healthcare providers worldwide.
The SOPHiA DDM™ Platform is utilised by over 780 hospitals, laboratories, and biopharmaceutical institutions across more than 70 countries. It supports a range of applications, including oncology, hereditary cancers, rare and inherited disorders, and radiomics. By aggregating and analysing diverse health data, the platform enables clinicians to make informed decisions, leading to personalised treatment plans and improved patient outcomes. SOPHiA GENETICS continues to pioneer advancements in precision medicine, aiming to democratise access to high-quality healthcare globally.
Shikha Negi is a Content Writer at ztudium with expertise in writing and proofreading content. Having created more than 500 articles encompassing a diverse range of educational topics, from breaking news to in-depth analysis and long-form content, Shikha has a deep understanding of emerging trends in business, technology (including AI, blockchain, and the metaverse), and societal shifts, As the author at Sarvgyan News, Shikha has demonstrated expertise in crafting engaging and informative content tailored for various audiences, including students, educators, and professionals.
